← SynDRA
NETARSUDIL-M1
SynDRA canonical compound SYN0040216 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PRKCA | ROCK1 |
|---|
| Mechanism of action | protein kinase c inhibitor |
|---|
| Indication | macular degeneration |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- ROCK2 INHIBITOR
- Rho-associated protein kinase inhibitor
- ROCK1 INHIBITOR
- rho associated kinase inhibitor
- SLC6A2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Drug classes
- Rho Kinase Inhibitor
- Rho Kinase Inhibitors
ATC classes
- S01E · ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Cross-references
Synonyms
- AR-13324 M1 metabolite
- AR-13503
- 4MVW7F3BCT
- Netarsudil metabolite AR-13503
- UNII-4MVW7F3BCT
- orb1710401
- SCHEMBL21412824
- SCHEMBL30607238
- BDBM50546246
- EX-A10925
- HY-12798C
- AKOS040732458
- AT38435
- T10358L
- DA-71006
- MS-24754
- SY346390
- CS-0043468
- HY-125639
- SCHEMBL9883166
- (rac)-AR-13503
- BDBM50156774
- orb1738360
- CS-0092566
- SCHEMBL30692376
Reported adverse events
- Eye pruritus
- Instillation site erythema
- Foreign body
Look up NETARSUDIL-M1 in the interactive SynDRA portal →